BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22098406)

  • 1. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.
    Abel GA; Vanderplas A; Rodriguez MA; Crosby AL; Czuczman MS; Niland JC; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; LaCasce AS
    Leuk Lymphoma; 2012 Jun; 53(6):1113-6. PubMed ID: 22098406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.
    Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy.
    Cheah CY; Dickinson M; Hofman MS; George A; Ritchie DS; Prince HM; Westerman D; Harrison SJ; Burbury K; Wolf M; Januszewicz H; Herbert KE; Carney DA; Tam C; Seymour JF
    Ann Hematol; 2014 Jul; 93(7):1193-200. PubMed ID: 24595733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
    Guppy AE; Tebbutt NC; Norman A; Cunningham D
    Leuk Lymphoma; 2003 Jan; 44(1):123-5. PubMed ID: 12691151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
    Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
    J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
    Shah HJ; Keraliya AR; Jagannathan JP; Tirumani SH; Lele VR; DiPiro PJ
    Korean J Radiol; 2017; 18(1):54-70. PubMed ID: 28096718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma.
    Hong J; Kim JH; Lee KH; Ahn HK; Park S; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
    Leuk Lymphoma; 2014 Oct; 55(10):2312-8. PubMed ID: 24428199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
    Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
    Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?
    Hutchings M; Polliack A
    Leuk Lymphoma; 2012 Jun; 53(6):1015-6. PubMed ID: 22545915
    [No Abstract]   [Full Text] [Related]  

  • 15. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
    Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J
    Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
    Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
    El-Galaly TC; Jakobsen LH; Hutchings M; de Nully Brown P; Nilsson-Ehle H; Székely E; Mylam KJ; Hjalmar V; Johnsen HE; Bøgsted M; Jerkeman M
    J Clin Oncol; 2015 Dec; 33(34):3993-8. PubMed ID: 26438115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
    Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
    Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.